Physician profile
Alvaro Ramirez
NPI 1093703696
$3,708.77
in general payments reported to CMS, 2019-2025
18 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $492 · 2021: $488 · 2022: $434 · 2023: $631 · 2024: $325 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,179.89 | 2019-2024 | Farxiga, Breztri |
| Gilead Sciences, INC. | $733.97 | 2019-2025 | Livdelzi |
| Glaxosmithkline, LLC. | $264.26 | 2021-2023 | Trelegy Ellipta |
| Abbvie INC. | $251.23 | 2021-2025 | |
| Amarin Pharma, INC. | $208.78 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $171.40 | 2023 | Linzess |
| Intra-Sana Laboratories | $140.38 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Lilly USA, LLC | $125.00 | 2019 | |
| Salvin Dental Specialties, INC. | $124.76 | 2021 | |
| Axsome Therapeutics, INC. | $109.46 | 2025 | Symbravo |
| Zealand Pharma US, INC. | $97.95 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $91.18 | 2020 | |
| Sumitomo Pharma America, INC. | $84.96 | 2023 | Gemtesa |
| Novo Nordisk INC | $48.10 | 2022 | |
| Theratechnologies INC. | $27.42 | 2023 | Egrifta, Trogarzo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $20.12 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $15.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvaro Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.